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Gamma-hydroxybutyrate (GHB) is a naturally occurring compound
found both in neural (Roth and Suhr 1970) and extraneural tissue (Nelson et
al. 1981 ). While the endogenous function of peripheral GHB has yet to be
elucidated, experimentation has found that this compound induces
anesthesia, and the release of growth hormone and prolactin from the
anterior pituitary (Oyama and Takiguchi 1970; Takahara et al. 1977). This
study was undertaken to determine the effect of chronic GHB injections on
the weight gain of rats during early postnatal development. Acute injections
were also administered to rats not previously treated with exogenous GHB to
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ascertain the mechanism of growth hormone release and to determine GHB's
effect on corticosterone release.
At the age of 3 days, both male and female rats from the chronic group
were injected intraperitoneally with 100 mg/kg, 500 mg/kg, or 0 mg/kg of
GHB. These injections were then performed twice a week for 38 days, with
the weight being recorded before each injection. Nine days following the end
of this injection period, those rats that had received 500 mg/kg of GHB, were
once again injected with of 500 mg/kg of GHB. The plasma was then
assayed for growth hormone and corticosterone levels. Rats in the acute
group were injected with 500 mg/kg GHB alone, or in combination with the
following: 1) chlorpromazine, a dopamine. receptor antagonist, 2)
cyproheptadine, a serotonin receptor antagonist, or 3) pyridoxine, a
dopaminergic system stimulator. The plasma growth hormone and
corticosterone were then determined using ELISA or RIA, respectively.
Results indicate that chronic GHB administration does not lead to
significant weight gain for male or female rats. Furthermore, chronic
administration of GHB leads to a reduction of GHB-induced growth hormone
release in male rats, possibly due to a receptor down-regulation. In contrast
to the males, na"ive female rats had no rise in plasma growth hormone
following GHB injection. Both chlorpromazine and cyproheptadine caused a
reversal of the GHB-induced rise in plasma growth hormone levels, indicating
possible action through both the dopaminergic and serotonergic systems.
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Pyridoxine leads to a decrease in GHB-induced growth hormone, leaving
some question as to the role of the dopaminergic system in GHB's activity.
Acute injections of exogenous GHB produced elevated plasma
corticosterone levels in males and females that were not responsive to the
dopamine and serotonin antagonists.
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Introduction

Gamma-hydroxybutyrate (GHB), shown in Figure 1, is a 4-carbon
compound containing a hydroxyl and carboxylic acid moiety, on primary
carbons 4 and 1 respectively. It was originally used experimentally to
determine if there existed a metabolic or physiological role for butyric acid
(Laborit 1964). The addition of the hydroxyl group was hoped to delay~oxidation, so these roles could be more firmly established (Laborit 1964). It
was known that this molecule is structurally similar to y-aminobutyric acid
(GABA), and it was thought that perhaps GHB might be able to cross the
blood-brain barrier (GABA cannot), and function as a GABA precursor
facilitating its synthesis in the brain (Laborit 1964; Feigenbaum and Howard
1996).

Figure 1. Chemical structure of y-hydroxybutyric acid.

GHB was found capable of rapidly crossing the blood-brain barrier
(Laborit 1964; Cash 1996; Feigenbaum and Howard 1996), and was
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discovered to be a natural metabolite, found in both neural (Roth and Suhr
1970) and extraneural tissues (Nelson et al. 1981 ). GHB was at one time
marketed as a health aid to persons with insomnia, and to bodybuilders as an
inducer of growth hormone release (Chin et al. 1992; Sanguineti et al. 1997).
Within 3 months of sales, it was banned in California and Florida due to acute
poisoning (Chin et al. 1992). Ingestion of the drug is reported to give a "high"
or disoriented effect, and it is easily synthesized illegally by dissolving sodium
hydroxide in near boiling gamma-butyrol lactone (Sanguineti et al. 1997).

Metabolism of GHB
GHB is widely considered to be primarily an endogenous metabolite of
GABA, and a pathway using this precursor for GHB formation is presented in
Figure 2. In the brain, GABA is converted into succinic semialdehyde (SSA)
by the enzyme GABA-transaminase (GABA-T). The SSA can then either be
oxidized and enter the citric acid cycle (Maitre 1996), or it can be reduced to
GHB by the action of a cytosolic enzyme, SSA reductase (SSR2) (Rumigny et
al. 1980). GHB has also been shown to be formed from 1,4-butanediol via
the action of an alcohol dehydrogenase in neural and extraneural tissues.
There are two enzymes known to oxidize GHB back to succinic
semialdehyde, GHB dehydrogenase (GHB-D) and GHB-oxoacid
transhydrogenase (GHB-T) (Nelson and Kaufman 1994). The former is a
cytosolic enzyme which catalyzes an NADP+ -dependent reaction that
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Figure 2. Metabolic pathway for GHB (Redrawn from Vayer et al. 1987).
Keys to intermediates are listed by number and enzymes are designated by
letters.
1) gamma-aminobutyric acid, 2) 1,4-butanediol, 3) gamma-butyrolactone, 4)
succinic semialdehyde , 5) GHB, 6) succinic acid.
A) GABA-transaminase, 8) alcohol dehydrogenase, C) peripheral lactonase,
D) SSA reductase, E) GHB-dehydrogenase, GHB-transhydrogenase, F)
Succinate dehydrogenase
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oxidizes GHB and reduces 0-glucuronate to L-gulonate (Kaufman and Nelson
1981). The latter is a mitochondrial enzyme that oxidizes GHB and
reduces an oxoacid such as a-ketoglutarate without the NADP+ requirement
(Kaufman et al. 1988).
In the brain, GHB-D is the predominant degradative enzyme for GHB
during the fetal and early neonatal period, while GHB-T takes over this role in
the later post-natal period. However in peripheral tissue, both enzymes have
active parts throughout development (Nelson and Kaufman 1994).
SSA can then be converted to succinate by SSA dehydrogenase, from
which it can enter the citric acid cycle and be metabolized for energy
(Kaufman and Nelson 1987).

Distribution of GHB
As previously indicated, GHB is found in both neural and extraneural
locations (Table 1). In the brain, GHB levels vary by region (Snead and
Morley 1981; Maitre 1997), and the highest concentrations are found in the
midbrain and in the caudate regions.
From a developmental standpoint, the highest levels of neural GHB are
found in neonates (400% higher than in adults) and decline significantly
through the postnatal period. GABA, succinic semialdehyde dehydrogenase
(SSDH), and GABA-aminotransferase are at their lowest levels during the
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prenatal period and increase through postnatal development (Snead and
Morley 1981 ). In the neonatal brain, the activity of the catabolic enzyme for
GHB is higher than the activity of the anabolic enzyme (GABA-T) required for
its synthesis from GABA, indicating that GABA is not the primary source of
GHB (Snead and Morley 1981).
GHB exists in various peripheral tissues, with concentrations being
greatest in brown fat, kidney, heart and muscle (see Table 1.). The high
levels of GHB found in these organs suggested that it must participate in
some way in their metabolism (Nelson et al. 1981). GABA is likely not the
precursor of GHB in extraneural tissue, as it is found in only trace amounts.

Table 1. Distribution of GHB in neural and peripheral tissues of adult rats
(Taken from Snead and Morley 1981; Maitre 1997).
Neural GHB (nmols/g)
Whole brain
2.29
Frontal cortex
0.4
Temporal cortex
5.75
Hippocampus
1.2
Striatum
1.8
Substantia nigra
4.6
Caudate
11 .4
Pons-medulla
4.68
Midbrain
15.0
Cerebellum
8.48

Peripheral GHB (nmols/g)
Heart
12.4
Kidney
28.4
Liver
1.42
Lungs
1.54
Muscle
10.2
Brown fat
37.4
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The GHB Receptor
Studies indicate that there are two classes of GHB binding sites, one
with high and the other with low affinity binding (Snead and Liu 1984). In the
CNS, GHB binding sites seem to exist only on neurons (Maitre 1997). The
receptor has not been sequenced, although it is known to be composed of
less than 10% protein, and the remaining structure is mainly composed of
lipid material (Cash 1996). Binding capacities have been shown to increase
with Mg 2•, although it is not an absolute requirement (Cash 1996). GHB
membrane binding sites are absent in peripheral tissue (Snead and Liu 1984;
Cash 1996).
A study by Snead (1992) on GHB-induced seizures found that rats
injected with pertussis toxin (PTX) were significantly protected from the
seizure associated effects of GHB. This suggested that GHB receptors were
associated with a G protein, as PTX is widely known to be an inhibitor of G
proteins through ADP-ribosylation (Voet and Voet 1995). Later analyses
found that in the presence of GTP, but not ATP, the binding affinity of GHB for
its brain membrane receptor is decreased significantly. This gives evidence
that the GHB receptor acts through a G protein, because in the presence of
GTP, the receptor-G protein complex dissociates to a point where a state of
low affinity receptor binding predominates (Ratomponirina et al. 1995). In
addition, ADP-ribosylation of the G proteins by PTX prevented them from
coupling to the GHB receptor.
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Some researchers have suggested that perhaps GHB is not the
primary ligand for this receptor, and that the ligand is a molecule yet to be
elucidated, because some psychotrophic substances that bear no structural
semblance to GHB have been found to bind to the receptor, with similar
affinity as GHB (Cash 1996).

Relationship to GABA
It is widely held that GHB is a GABA receptor agonist. This concept is
largely due to the original assumption that GHB is primarily derived from
GABA. However, there is substantial evidence which suggests that GHB is
not exclusively derived from GABA endogenously (Feigenbaum and Howard
1996). A study by Snead et al. (1982) found that inhibiting the formation of
GABA has no significant effect on GHB levels in the rat brain. GHB has only
a slight effect on GABAnergic mechanisms, and even this may be indirect
(Feigenbaum and Howard 1996). Of the two subtypes of GABA receptors,
GHB is unable to serve as an agonist to the GABAA receptor (Mathivet et al.
1997), but it is a weak agonist of the GABA 8 receptor (Mathivet et al. 1997;
Nissbrandt and Engberg 1996; Snead 1996).

Physiological Effects of GHB
Early research on cats, and later humans, indicated that
administration of GHB caused depression of the central nervous system
(Roth and Gairma 1966). However, initial researchers were uncertain if the
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depressive effects were caused by GHB or its precursor, y-butyrolactone
(GBL), both of which had been used in the experiments. It was soon
determined that the physiological effects of exogenously administered GBL
was attributed to the conversion into GHB by lactonase which is present in
the blood serum (Roth and Gairman 1966).
When the amount of GHB in the brain reaches the critical level of 70
mg/kg, the animals lose their righting reflex and a state of anesthesia ensues
(Giarman and Roth 1964). The LD50 in rats was shown to be 1.7 g/kg with
respiratory depression as the cause of death (Laborit 1964).
During periods of hypoxia, GHB has been demonstrated to increase
the survival time in the animals studied (Atru et al. 1980), and this action is
thought to be caused by depressing the cerebral metabolic rate. Under
extreme anoxic conditions, the most favorable reaction for an animal is the
reduction of succinic semialdehyde into y-hydroxybutyric acid, leading to the
formation of NAD+ reserves, which are in short supply during hypoxia and can
be used to eliminate excess lactate. During exercise, GHB can also be
converted into succinic acid, which can enter the Krebs cycle upon
conversion to succinate (Kleimenova et al. 1979). In addition, GHB causes a
slight drop in body temperature leading to hypothermia, and appears to
protect against convulsions (Laborit 1964).

8

GHB has also been used experimentally to control alcohol dependence
since GHB and ethanol share some chemical and pharmacological
properties. Both are short carbon chains containing hydroxyl groups, and
both have anesthetic and motor impairing effects. Columbo et al. (1994)
demonstrated that GHB has a suppressing effect on voluntary alcohol intake,
and ultimately reduces the amount of ethanol consumption by alcohol
dependent test animals. Fadda et al. (1989) has found that GHB was able to
antagonize ethanol withdrawal syndrome in rats. It was demonstrated that a
significant protection was provided at lower than anesthetic doses. In
addition, chronic ethanol intake confers tolerance to the sedative and
anaesthetic effect of GHB.
Takahara et al. (1977) evaluated the role that GHB played in regulating
the secretion of pituitary hormones. They found that GHB caused a
significant rise in the plasma levels of prolactin (PRL) and growth hormone
(GH) (Oyama and Takiguchi 1970; Takahara et al. 1977). Takahara et al.
(1977) suggested the release of prolactin might be associated with a possible
decrease in the release of dopamine from the hypothalamus (see next
section), as dopamine is also known as prolactin inhibiting factor (PIF)
(Porterfield 1997). GHB might induce serotonin release from its nerve
terminals stimulating the release of prolactin and GH (Takahara et al. 1977).
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It has not yet been determined what long term effects GHB will have on body
mass (Chin et al. 1992).

Possible Mechanisms of Actions of GHB on Hormone Release
While the metabolic and physiological roles of GHB have undergone
extensive research, many of the mechanisms of its action are not well
understood (Chin et al. 1992).
GHB and opium induce similar effects, so researchers hypothesized
that possibly GHB has some action through the opiate system, possibly as an
opiate agonist (Feigenbaum and Simantov 1996). However, studies have
shown that naloxone, an opiate receptor antagonist, could not block the GH
releasing effect of GHB (Gerra et al. 1995). In addition, there was only
negligible binding of GHB to theµ, 6 and K subtypes of the opiate receptor at
any concentration of GHB (Feigenbaum and Simantov 1996). This suggests
that GHB does not work directly through the opiate system.
A large body of evidence indicates that GHB might have a strong
influence on the dopaminergic system by serving as a relatively specific
inhibitor of dopamine release (Feigenbaum and Howard 1996a). It is known
that dopamine and its agonists increase the hypothalamic secretion of GHRH
(Brambilla et al. 1997). GHB is capable of significantly inhibiting impulse flow
of dopamine through central dopamine neurons, presumably by action on
their storage granular membranes (Feigenbaum and Howard 1996a; Menon
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et al. 1974). This inhibition of release resulted in an increase in central
dopamine (DA) levels (Roth and Suhr 1970). GHB has also been found to
inhibit rather than enhance dopamine releasing agents, and enhance drugs
that block dopamine release (Feigenbaum and Howard 1996a). A lengthy
inhibition of DA release might disinhibit DA autoreceptors resulting in an
increased expression and activity of tyrosine hydroxylase (the rate-limiting
enzyme in DA biosynthesis), explaining the increase in DA synthesis that has
been observed (Roth and Suhr 1970; Feigenbaum and Howard 1996a).
Research by Volpi et al. (1997) revealed that in patients with
Parkinson's disease, GHB was still able to cause GH secretion whereas
GABA was not. This suggests that GHB is not working through a
GABAnergic pathway as many earlier researchers had assumed, and
indicates it is acting, in this case, through non-dopamine mediation, such as
serotonergic neurotransmission or through a cholinergic pathway.
It has been demonstrated that alpha-2 receptor-stimulated GH release
is mediated by serotonergic neurotransmission (Conway et al. 1990; Smythe
et al. 1975). The ability of the serotonin receptor antagonist, metergoline, to
decrease GHB-induced GH release indicates GHB action may be through the
serotonergic system (Gerra et al. 1995). Research has shown that GHB
caused no marked changes in norepinephrine levels (Roth and Suhr 1970),
but does increase serotonin concentration (Walmeler and Fehr 1978).
Hedner and Lundborg (1983) found that GHB does not change the
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endogenous brain concentration of 5-hydroxytryptamine (5-HT, serotonin),
however it does cause an increase in the rate of 5-HT synthesis and
degradation (Hedner and Lundborg 1983). Additional research by Vescovi
and Coiro (1997) found that alcoholics showed a down regulation in the
serotonin receptor subtype 5-HT1 D. In this instance, GHB is unable to cause
the release of GH.
GH is thought to act as an adrenal secretagogue, and cause
decreased cortisol clearance and metabolism, or possibly a decrease in
serum cortisol binding globulin leading to increased serum free cortisol in
humans with elevated GH (Weaver et al. 1994). Previous research on human
subjects have found that plasma cortisol rose significantly following acute
GHB administration (Oyama and Takiguchi 1970). In rats, corticosterone
serves as the primary glucocorticoid instead of cortisol (Griffin and Ojeda
1996). The effect of GHB on plasma corticosterone levels has not been
analyzed experimentally in rats.
The ability of GHB to increase GH levels may be a model to indirectly
evaluate the hypothalamic action of this drug (Gerra et al. 1995). The
secretion of GH is under the control of the CNS, through action of two specific
hypothalmic neuropeptides released from hypophyseal-portal system, GHreleasing hormone (GHRH), and somatostatin (SS). The actions of GHRH on
the somatotrophs of the anterior pituitary are stimulatory while the effects of
SS are inhibitory (Argente et al. 1996; Conway et al. 1990; Muller et al. 1995).
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Research obiectives
The primary goals of this research were to examine the action of GHB
on GH release in rats, as well as to determine if there was an effect on
plasma corticosterone levels. There were seven major questions asked in this
research. During the early postnatal period will exogenous GHB 1) increase
the body mass of rats in a dose dependent fashion, 2) alter basal GH levels,
and 3) result in alterations in the development of tissues such as the
adrenals and gonads? In adult rats, 4) what pathway does GHB use to cause
the release of GH, 5) what effect will GHB have on the release of
corticosterone, 6) would chronic administration of GHB reduce GHB-induced
effects, and 7) what response variations exist between male and female rats?
It is hypothesized in this study, that GHB is able to cause the release
of GH by increasing modular action of a neurotransmitter on the release of
GHRH or SS. It is also hypothesized that this release of GH through chronic
injections of GHB will result in a dose-dependent increase in weight gain in
both male and female rats. And finally, it is hypothesized that GHB
administration will result in an increase in plasma corticosterone, similar to
that seen for cortisol in humans.

Rationale for Using Neurotransmitter Antagonists and Agonists
As indicated in the previous sections, GHB has an effect on the levels
of serotonin and dopamine found in the brain, and both of these
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neurotransmitters have been shown to influence the release of GH from the
anterior pituitary. In order to elucidate if the ~HS-induced GH release is due
to either of these transmitters, the following drugs were used in conjunction
with GHB: Chlorpromazine, cyproheptadine and pyridoxine.
Cyproheptadine is a serotonin receptor antagonist (Conway et al.
1990; Smythe et al. 1975), capable of completely blocking the ability of 5HT
to elevate serum GH levels in rats at

a: dosage of 10 mg/kg (Smythe et al.

1975). If this drug reverses the effect of GHB, it may be assumed 5HT plays
a role in GHB mediation.
Chlorpromazine is a dopamine receptor antagonist (Menon et al. 1974;
Porterfield 1977; Sato et al. 1995) capable of reversing the effects of
dopamine. If administration of this drug hinders the ability of exogenous GHB
to elevate serum GH levels, this would indicate dopamine plays a key role in
GHB mediation.
Pyridoxine is a drug which helps facilitate the decarboxylation of Ldopa to dopamine by acting as a coenzyme of Dopa carboxylase. In this
manner, pyridoxine by elevating dopamine levels (Delitala et al. 1976; Reiter
and Root 1978), causes a significant rise in GH levels within 60 minutes of
administration, while simultaneously decreasing prolactin levels (Delitala et al.
1976). If this drug is capable of enhancing GHB action, it would strongly
suggest dopaminergic involvement.
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Methodology

Animals
Pregnant rats were purchased from Harlan Sprague Dawley, and
placed in standard plastic cages with wood chip bedding, and housed in the
animal care facility in Lappin Hall. The ambient temperature was maintained
at approximately 22 °C, with a 12-hour lighVdark cycle. Both food and water
were freely available throughout the experiment. Twenty-four days after birth,
the juvenile rats were weaned and separated into groups of three.

Drugs
Gamma-hydroxybutyrate (sodium salt), pyridoxine, chlorpromazine,
and cyproheptadine were purchased from the Sigma Chemical Co.
Cyproheptadine was dissolved in 50% (v/v)·ethanol, and the other three drugs
were dissolved in physiological saline (0.9% sodium chloride w/v). All drugs
were at room temperature when administered.

Chronic Experiment
The chronic experiment is summarized on the left side of the protocol
flow chart in Figure 3. On the third postnatal day, the rat pups were sexed
and weighed. The male and females were divided into three groups, with
each group containing 5 males and 4 females. The first group received 100
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mg/kg of GHB, the second received 500 mg/kg of GHB, and the last group
received of 0.9 % saline, which was used as a placebo. These amounts of
GHB are well within the range of previous studies (Atru et al. 1980, Colombo
et al. 1994, Fadda et al. 1989). All injections were performed intraperitoneally
using a 1 cc syringe with a 27 gauge needle, with a total volume of 0.1 cc. The
pups were weighed and injected twice a week at approximately 5:00 p.m., for
'

a period of 38 days.
At the end of the 38 days, the rats were euthanized using a small
animal guillotine, and blood was collected in heparinized 15 ml test tubes.
The pituitary, left kidney, left adrenal, and left testis/ovary were removed from
each animal, cleaned of excess fatty tissue, and weighed.

Acute experiment

The protocol for the acute experiment is shown in the right side of the
flowchart in Figure 3. Male and female rats, 7 weeks of age, were divided
into 5 groups and weighed. The first group received an injection of
physiological saline only (4 males, 4 females). Group 2 was injected with
GHB, 500 mg/kg (5 males, 4 females). Group 3 was injected with
chlorpromazine, 42.6 mg/kg (5 males, 3 females}. Group 4 was injected with
pyridoxine, 20 mg/kg (4 males, 3 females). The last group, group 5, was
injected with cyproheptadine, 10 mg/kg (5 males, 4 females). Fifteen minutes
following the first injection, groups 3-5 received an injection of GHB,
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Figure 3. Overview of experimental design.
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500 mg/kg. The total volume of each injection was 0.2 cc. The initial
injections were performed at approximately 1:00 p.m. After a period of 70
minutes following the GHB injection, the animals were euthanized using a
small animal guillotine.
The time period between removing the rat from its cage and sacrificing
the animal was kept short as possible to prevent a raise in corticosterone
levels. Blood collected from each rat upon sacrifice was centrifuged to
separate the plasma. The plasma was then frozen at -20°C until it could be
analyzed.
To determine the effect of chronic exposure of exogenous GHB on
growth hormone release, 5 male and 4 female rats, from the chronic
experiment also received an injection of GHB, 500 mg/kg/0.2cc. These rats
had not received GHB for 9 days to determine if there was a long-lasting
effect. The rats were sacrificed and plasma analyzed in the same manner as
the rats from the acute experiment.

Growth Hormone Assay
Determination of rat plasma growth hormone (rGH) was made using an
enzyme immunoassay (EIA) system (Amersham International). Plasma
samples were diluted 1 :5 in assay buffer [0.025M phosphate buffer pH 7.5
containing 0.1 % sodium azide.] Standards were prepared using serial
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dilutions (1.6, 4.1, 10.24, 25.6, 64, 160 ng/ml) from a rat growth hormone
(rGH) stock solution of 400 ng/ml. Fifty microliters of the plasma samples and
rGH standards were pipetted into individual wells of a microtitre plate, coated
with anti-goat lgG. An equal volume of antiserum (goat anti-rGH serum) was
then added to each well, and allowed to incubate at room temperature for 3
hours. After the incubation period, 50 µI of rGH conjugate was pipetted into
each well and incubated at room temperature for 30 minutes. The wells were
then aspirated with a pipette and washed with wash buffer (0.01 M phosphate
buffered saline pH 7.4 containing 0.2% Tween). A 100 µI aliquot of Amdex
was then added to each well and allowed to incubate at room temperature for

30 minutes. Amdex is an amplification reagent that contains a straight chain
dextran backbone covalently bound to hundreds of horseradish peroxidase
molecules (Amersham 1996). The wells were again aspirated and washed.
For the color forming reaction, an 100 µI aliquot of TMB substrate (3,3' ,5,5'tetramethylbenzidine/hydrogen peroxide solution, in 20% dimethylformamide)
was added to each well, and allowed to react at room temperature for a
period of 30 minutes. The reaction was ended with the addition of 100 µI of
1M H2 S04 . The microtitre plate was then analyzed for optical density (OD)
using a MR 600 microplate reader (Dynatech Laboratories, inc.) at 450 nm.
All samples and standards were run in duplicate.
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The rGH level of each sample was determined using a standard curve
generated from the optical densities of the known rGH concentrations using
Microsoft Excel.

Corticosterone Assay
Determination of plasma corticosterone was made using a
radioimmunoassay (RIA) kit (ICN Biomedicals, Inc.). Plasma samples were
pipetted into glass tubes and diluted 1 :500 in steroid diluent. The tubes were
then incubated at 98 °C in an lsotemp water bath (Fisher Scientific) for 10
minutes. With the exception of the blank, 100µ1 of anti-corticosterone was
pipetted to the assay tubes. A 100µ1 volume of corticosterone-3H tracer
(-10, 000 cpm/1 00µ1) was then pipetted to all of the reaction tubes, and the
tubes were mixed and incubated at 4°C for 16 hours.
Following the incubation, 200µ1 of charcoal dextran solution (4°C) was
added and the tubes were mixed and incubated for 20 minutes. The tubes
were then centrifuged at 2500 rpm for 15 minutes at 4°C, using a Marathon
21 K/BR centrifuge (Fisher Scientific). The supernatant was then decanted
into scintillation vials. A volume of 16 ml of scintillation fluid was then added
to each vial and counts per minute (cpm) were recorded using a Beckman
scintillation counter (LS 5801 Series).
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All samples and standards were run in duplicate. The corticosterone
levels of each sample was determined using a standard curve generated from

the cpm of known corticosterone concentrations using Microsoft Excel.

Statistical Analysis

Analysis of variance (ANOVA) was used to determine if a significant
difference existed between groups. In the chronic study, all groups were
compared to the group receiving the placebo, while in the acute experiment
groups were compared against those receiving 500 mg/kg of GHB. The
ANOVA and graphical data were performed using Microsoft Excel. In all
graphs, points represent the mean ± the standard error value for each group
indicated.
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Results

The administration of 500 mg/kg of GHB in both the chronic and acute
experiments was observed to produce an anesthetic effect immediately
following the injections. This sedative state lasted for approximately two
hours.

Chronic Experiment
The effect of chronic GHB injections on male and female rats are
shown in Figures 4 and 6 respectively. To eliminate the possibility that
discrepancies in the starting weights of the animals had some impact on the
study, each day the animals were weighed, the weights were standardized by
simply dividing by the starting weight of each animal. This information is
shown in Figures 5 and 7.
For both the males and females, analysis of variance revealed no
significant difference between the groups injected with GHB, both 100 mg/kg
and 500 mg/kg, and the control group (F<5.3, p>0.05). However, while they
may have not been significant, different trends do seem to exist between the
males and females. For the males, the highest weight gain was obs_erved in
the group receiving 100 mg/kg GHB, and the lowest weight gain was
observed in the group receiving 500 mg/kg GHB (Day 38, F=0.6727,
P=0.4358), with the difference growing closer to significant over time.
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For the females, injection of both 100 mg/kg and 500 mg/kg led to a
slight increase in body weight over the group receiving the placebo.
When the weights of the organs were analyzed, it was found that for
the males, there was no significant difference between the groups receiving
GHB, either 100 mg/kg or 500 mg/kg, and those receiving saline (F<5.1174,
.P>0.05). The mean weights for each group is shown in Table 2.
Table 2. The effect of chronically administered y-hydroxybutyrate on the
organ development of male rats. All weights are expressed as grams of
tissue per kilogram of total animal mass.

Control
100 mg/kg
500 mg/kg

Pituitary Left Kidney Left Adrenal Left Testis
0.0334
4.4546
0.1102
5.6247
0.0343
4.3123
0.1012
5.4714
0.0337
4.4093
0.0999
5.7095

For the females, there was also no significant difference in organ
weights between the groups. The groups receiving 100 mg/kg GHB showed
, a considerable discrepancy in the weights of the left kidney and left adrenal
(F=3.8157, P=0.0935; F=1.0451, P=0.3407 respectively) between the groups.
The mean values for these groups are listed in Table 3.
Table 3. The effect of chronically administered y-hydroxybutyrate on the
organ development of female rats. All weights are expressed as grams of
tissue per kilogram of total animal mass.

Pituitary Left Kidney Left Adrenal Left Ovary
Control
0.0382
4.3301
0.1499
0.3149
100 mg/kg
0.0384
4.4137
0.1343
0.3704
500 mg/kg
0.0404
4.3599
0.1361
0.3670
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Acute Experiment
Growth Hormone Assa;
As shown in Figure 8, administration of GHB in males led to a nonsignificant increase of plasma GH to 260 ng/ml from a mean of 176 ng/ml in
the controls. The male rats receiving the dopamine receptor antagonist
chlorpromazine had their plasma GH return to the basal level of 175 ng/ml
(P=0.5195: F=0.4539), and those male rats receiving the serotonin receptor
antagonist, cyproheptadine, had the plasma GH levels fall to 145 ng/ml (P=
0.3192; F= 1.128). The rats receiving the Dopa carboxylase coenzyme,
pyridoxine, had their plasma GH fall to 32 ng/ml (P=0.0983; F=3.636).
For male rats that had received chronic injections of GHB throughout
their post natal development, administration of 500 mg/kg of GHB did not
produce an increase in plasma GH, while an elevation of plasma GH did
occur in the male na'ive rats receiving the first injection (500mg/kg) of GHB
(P=0.1166; F=3.094).
As indicated in Figure 9, GHB administration to female rats did not
cause the increase in plasma GH as seen for the males. Instead GH levels
fell from 176 ng/ml in the control to 115 ng/ml (P=0.2421, F=1.684).
Compared to the controls, non-significant reductions in plasma GH levels in
female rats were observed following acute injections of chlorpromazine [95
ng/ml (P=0.5010, F=0.5254)], cyproheptadine [83 ng/ml (P=0.2394,
F=1.706)], and pyridoxine [78 ng/ml (P=0.2189, F=1.975)].
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For the female rats that had received chronic injections of GHB, the
acute administration of the drug caused virtually no change in plasma GH
levels compared to that of the control group, and had a P-value of 0.1397 and
F-value of 2.896 compared to the na"ive group receiving GHB.

Corticosterone Assay
As shown in Figure 10, administration of GHB to male rats, caused a
tremendous increase in plasma corticosterone levels, when compared to
saline-injected controls. This increase from 19 ng/ml to 431 ng/ml was
significant (P=0.0009, F=37.215). This effect was not abated by any of the
drugs given in combination, and in fact all reported levels are higher, although
not significantly. The group receiving chlorpromazine had a mean plasma
corticosterone level of 464 ng/ml, while the group receiving cyproheptadine
had a concentration of 580 ng/ml (P=0.0869, F=3.959). The final group
receiving pyridoxine had a plasma corticosterone level of 512 ng/ml. All
groups were significantly elevated from the controls, but there were no
significant differences between the treatment groups.
For the male rats that had received chronic injections of GHB, the
acute administration of the drug (500 mg/kg) resulted in the same increase in
plasma corticosterone, 483 ng/ml, as seen in the na"ive rats that received the
500 mg/kg dosage (see Figure 10).
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As illustrated in Figure 11, the administration of 500 mg/kg of GHB to
female rats caused a significant rise in plasma corticosterone as seen in the
male rats, which had received the 500 mg/kg dosage (P=0.0004, F=50.762).
The addition of the serotonin and dopamine receptor antagonists and the
coenzyme for Dopa carboxylase did not alter the effect of GHB. The female
groups receiving chlorpromazine, cyproheptadine, and pyridoxine had mean
plasma corticosterone concentrations of 555, 776, and 670 ng/ml
respectively.
Unlike the males however, the female rats that had received chronic
injections of GHB, had a significantly reduced effect on GHB induced
corticosterone release, 103 ng/ml (P=0.0153, F=11.268). This was an 80%
reduction.
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Discussion

Previous research has indicated that GHB leads to the release of GH
(Oyama and Takiguchi 1970; Takahara et al. 1977), a hormone that has a
definite growth promoting function (Griffith and Ojeda 1996). As indicated in
Figure 5, chronic injections of y-hydroxybutyrate did not result in ,any
significant increases in the masses of developing male rats. In fact, the group
receiving the highest dosage, 500mg/kg, had the smallest amount of total
body mass. Failure to measure a significant increase in mass may be due to
several factors. GH is known to be released endogenously in a pulsatile
manner (Jaffe et al. 1998). Chronic injections of GHB, as were performed in
this research, may lead to an inability of the drug to stimulate GH release,
therefore consecutive injections could not result in additional growth.
Evidence for this is shown in Figure 8, in which male rats that had previously
been injected chronically (indicated on the bar graph as chronic) with GHB for
a period of 38 days failed to exhibit a rise of plasma GH in response to a
acute injection of 500 mg/kg of GHB. This effect may be caused by the large
dose of GHB leading to a down regulation of GHB receptors, or perhaps by a
down regulation of an intermediate's receptors in the pathway, such as
dopamine or serotonin. Recent research by Ratomponirina et al. (1998)
found that chronic peripheral administration of 500 mg/kg of GHB rapidly
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down-regulates GHB receptors in rats. This effect is long lasting or possibly
even permanent, since the rats in the group chronically injected with 500
mg/kg of GHB had not been injected for a period of 9 days before the acute
portion of the experiment. It is of interest to note that the male rats achieving
the highest amount of weight gain were those receiving 100 mg/kg. While not
statistically significant, weight gain was higher in this group than the control.
This suggests that perhaps at this lower dosage, chronic injections do not
lead to receptor down regulation.
For the chronically treated females (Figure 7), administration of both
the 100 and 500 mg/ml concentrations of GHB resulted in slight increases in
mass over time, 6.6 and 3.9 % respectively. This is interesting since acute
administration of GHB in female rats did not result in elevated growth
hormone levels (see Figure 9).
In an effort to elucidate the mechanism of action by which GHB causes
the release of GH, the effects of chlorpromazine and cyproheptadine were
determined. In both male and female rats, each of these drugs caused a nonsignificant decrease in the GH release induced by GHB (Figures 8 and 9).
The dopamine antagonist chlorpromazine led to 33% and 17% reduction of
GHB induced GH release in males and females respectively, whereas, the
serotonin antagonist cyproheptadine resulted in 44% and 28% reductions in
males and females respectively. Such reductions in GH release caused by
these antagonists suggest both dopamine and serotonin are involved in the
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mechanism involved in y-hydroxybutyrate's GH releasing activity, with
serotonin having a more prominent role as in the case of normal basal
secretion (Conway et al. 1990).
Pyridoxine (Vitamin B6) is metabolized in vivo to pyridoxal-5'phosphate which can function as a cofactor for dopa decarboxylase which
converts L-dopa to dopamine (Delitala et al. 1976; Geraldet al. 1982). The
effect of 20 mg/kg of this cofactor on GHB induced GH release is intriguing.
In males, the drug caused a 88% reduction in GH release, and a 32%
'

reduction in females. This result is quite unexpected since pyridoxine
produces the release of growth hormone in normal human subjects (Delitala
et al. 1976). A possible explanation is that pyridoxine has a more rapid effect
on G H release than does G HB, and by the time the serum was assayed, the
hormone may have been cleared from the plasma. However, in humans the
maximum GH peak occurs more rapidly as a result of GHB injection than by
pyridoxine injection (Delitala et al. 1976; Takahara et al. 1977). In rats, growth
hormone has a plasma half life of 5-6 minutes (Badger et al. 1991; Goya et al.
1987) so if pyridoxine does cause a rapid plasma GH surge, it may be cleared
before the analysis took place. These results coincided with past research
that has found GHB inhibits rather than enhances dopamine releasing agents
(Feigenbaum and Howard 1996a). If this is the case, the reduction in GH
secretion caused by chlorpromazine may just be due to action on the normal
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pathways for basal GH release, as opposed to action on the GHBnergic
system.
Further research should be devoted to determining possible action by
the adrenergic and cholinergic systems on the GHB pathway. Evidence
suggests that, in normal conditions, the catecholaminergic and cholinergic
systems stimulates GH secretion by releasing GHIH and inhibiting SS, and
the release of adrenaline regulates its pulsatile secretion by action on its
alpha and beta receptors (Argents et al. 1996; Muller et al. 1995).
The discrepancies between the male and female responses to GHB is
quite intriguing, and is not easily explained, since previous research on this
subject has been performed almost exclusively on males. One explanation is
the sexual dimorphism in the regulation of GH secretion that exists between
normal male and female rats (Jaffe et al. 1998). Males tend to have large
infrequent pulses, predominately during sleep, whereas females have smaller
more uniform pulses throughout the day (Jaffe et al. 1998; Muller et al. 1995).
This difference is thought to be caused primarily by the more prominent role
of hypothalamic somatostatin (SS) in males than in females (Jaffe et al.
1998).
GHB was found in this research to have the ability to increase the
concentration of plasma corticosterone in both male and female subjects by a
factor of 10-20 fold (Figures 10 and 11 ). The mechanism for this release is
not known. However, it is probably not due to the release and consequent
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action of growth hormone as described by Weaver et al. (1994), since the
females without the increased GH levels also had this elevated corticosterone
release. GHB may again be acting in the hypothalamus, causing the release
of corticotropin-releasing hormone (CRH) which could in turn release
adrenocorticotropin hormone (ACTH) from the anterior pituitary, and
ultimately cause the release of corticosterone from the adrenal gland. CRH
secretion from the hypothalamus has been found to be stimulated in response
to-norepinephrine, acetylcholine, serotonin, and dopamine (Calogero et al.
1988; Calogero et al. 1989a; Calogero et al. 1989b). Caloogero et al. 1988
also suggests that CRH secretion is weakly stimulated by epinephrine and
dopamine. However, when used in combination with GHB, the dopamine and
serotonin receptor antagonists, chlorpromazine and cyproheptadine, were
unable to prevent the GHB induced corticosterone release, indicating these
two particular neurotransmitters appear not to be involved in GHB's
corticosterone releasing process.
Another possible mechanism to explain the elevation of corticosterone
is that GHB could be prompting the release of ACTH by acting directly on
corticotrophs in the anterior pituitary. Finally, GHB may be acting directly on
the cells of the adrenal cortex causing the release of corticosterone. These
possible modes of stimulation were not studied in this research.
For the male rats, chronic injection of GHB had no effect on sensitivity
for animals to release corticosterone (Figure 10). For the females however,
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chronic administration of GHB decreased the drug's ability to release
corticosterone by 80% (see Figure 11 ). A study by Ogilvie and Rivier (1997)
found that female rats secrete more ACTH and corticosterone than male rats
in response to the same amount of ethanol. This effect appears to be ·
dependent on the sex hormone estradiol (Nowak et al. 1995; Ogilvie and
Rivier 1997). If this increased ACTH release also holds true for GHB, then
perhaps chronic injections of the drug would result in a more rapid ACTH
receptor down regulation in female rats than males.

Conclusion
The primary goals of this research were to examine the action of GHB
on GH and corticosterone release in both chronic and acute experiments.
While the receptor antagonists for the neurotransmitters serotonin and
dopamine were able to reduce GHB effects, results indicate that GHB did not
significantly stimulate GH secretion in either sets of experiments at the doses
of 100 mg/kg and 500 mg/kg used in this research. Consequently, there was
no dose dependent weight increase caused by this drug. However, injections
of GHB did cause significant increases in plasma corticosterone.
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